Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Bristol-Myers Squibb’s Alzheimer’s Study Results

By Drug Discovery Trends Editor | July 20, 2011

 Bristol-Myers Squibb Company announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer’s disease.

BMS-708163 is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta (A?) synthesis. A? is hypothesized to play a central role in the development of Alzheimer’s disease. In healthy people, A? breaks down and is eliminated; but in people with Alzheimer’s disease, A? accumulates and forms “amyloid plaques” in the brain. While the chain of events that lead to the development of Alzheimer’s is still unclear, the accumulation of A? and the resulting formation of amyloid plaques are considered hallmarks of the disease pathology.

The randomized, double-blind, placebo-controlled study (CN156-013) demonstrated that BMS-708163 doses below 100 mg/day provide a potential therapeutic window for further evaluation in Phase III registrational studies.

Of the four BMS-708163 doses evaluated in the study (25 mg, 50 mg, 100 mg and 125 mg/day), doses below 100 mg/day demonstrated acceptable tolerability profiles for further development and were associated with discontinuation rates comparable with placebo. BMS-708163 doses at or above 100 mg were associated with higher discontinuation rates, most commonly due to gastrointestinal and dermatological side effects.

“The safety and tolerability results of this Phase II study in mild-to-moderate Alzheimer’s disease support the further clinical evaluation of Bristol-Myers Squibb’s gamma secretase inhibitor,” says Stephen Salloway, MD, professor of neurology and psychiatry, Brown University, and director, The Butler Hospital Memory and Aging Program.

Release Date: July 20, 2011
Source: Bristol-Myers Squibb Company 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE